SK283021B6 - Spôsob výroby sterilného lyofilizátu cetrorelixu - Google Patents

Spôsob výroby sterilného lyofilizátu cetrorelixu Download PDF

Info

Publication number
SK283021B6
SK283021B6 SK195-94A SK19594A SK283021B6 SK 283021 B6 SK283021 B6 SK 283021B6 SK 19594 A SK19594 A SK 19594A SK 283021 B6 SK283021 B6 SK 283021B6
Authority
SK
Slovakia
Prior art keywords
solution
cetrorelix
weight
injection
water
Prior art date
Application number
SK195-94A
Other languages
English (en)
Slovak (sk)
Other versions
SK19594A3 (en
Inventor
J�Rgen Engel
Burkhard Wichert
Dieter Sauerbier
Thomas Reissmann
Original Assignee
Zentaris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6480924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK283021(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zentaris Ag filed Critical Zentaris Ag
Publication of SK19594A3 publication Critical patent/SK19594A3/sk
Publication of SK283021B6 publication Critical patent/SK283021B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacture Of Tobacco Products (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SK195-94A 1993-02-19 1994-02-18 Spôsob výroby sterilného lyofilizátu cetrorelixu SK283021B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4305225A DE4305225A1 (de) 1993-02-19 1993-02-19 Neues Herstellverfahren für Cetrorelix Lyophilisat

Publications (2)

Publication Number Publication Date
SK19594A3 SK19594A3 (en) 1994-09-07
SK283021B6 true SK283021B6 (sk) 2003-02-04

Family

ID=6480924

Family Applications (2)

Application Number Title Priority Date Filing Date
SK195-94A SK283021B6 (sk) 1993-02-19 1994-02-18 Spôsob výroby sterilného lyofilizátu cetrorelixu
SK810-2001A SK283022B6 (sk) 1993-02-19 1994-02-18 Liečivo na liečenie ženskej neplodnosti a na ochranu pohlavných žliaz

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK810-2001A SK283022B6 (sk) 1993-02-19 1994-02-18 Liečivo na liečenie ženskej neplodnosti a na ochranu pohlavných žliaz

Country Status (29)

Country Link
EP (2) EP0947200B1 (ko)
JP (1) JP4033919B2 (ko)
KR (2) KR100355686B1 (ko)
CN (1) CN1109557C (ko)
AT (1) ATE193653T1 (ko)
AU (1) AU671881C (ko)
BR (1) BR9400617A (ko)
CA (1) CA2115943C (ko)
CZ (2) CZ285768B6 (ko)
DE (2) DE4305225A1 (ko)
DK (1) DK0611572T3 (ko)
ES (1) ES2148247T3 (ko)
FI (1) FI110059B (ko)
GR (1) GR3034237T3 (ko)
HR (1) HRP940117B1 (ko)
HU (1) HU218281B (ko)
IL (1) IL108704A (ko)
MX (1) MX9401312A (ko)
NO (1) NO316601B1 (ko)
NZ (2) NZ314707A (ko)
PL (1) PL177177B1 (ko)
PT (1) PT611572E (ko)
RU (1) RU2145234C1 (ko)
SG (1) SG46632A1 (ko)
SI (1) SI9400087B (ko)
SK (2) SK283021B6 (ko)
TW (1) TW387812B (ko)
UA (1) UA43829C2 (ko)
ZA (1) ZA941136B (ko)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828415B2 (en) * 1993-02-19 2004-12-07 Zentaris Gmbh Oligopeptide lyophilisate, their preparation and use
AR006598A1 (es) * 1996-04-19 1999-09-08 Merck Sharp & Dohme "composiciones anti-fungosas, su uso en la manufactura de medicamentos y un procedimiento para su preparación"
DE19712718C2 (de) * 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
AU752415B2 (en) * 1998-04-23 2002-09-19 Zentaris Ivf Gmbh Method for the treatment of fertility disorders
DE10024451A1 (de) 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
DE10040700A1 (de) * 2000-08-17 2002-02-28 Asta Medica Ag Salze von biologisch aktiven Peptiden, ihre Herstellung und Verwendung
US20030186892A1 (en) * 2002-03-28 2003-10-02 Rajneesh Taneja Enhancement of endogenous gonadotropin production
RS20050247A (en) 2002-09-27 2007-06-04 Zentaris Gmbh., Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
EP1987843A3 (en) 2004-03-12 2011-10-26 Intercell AG Method for solubilising peptide mixtures
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
CN101630607B (zh) * 2008-07-19 2012-04-25 浙江家泰电器制造有限公司 液体加热器皿过热保护控制器组件
CN101629758B (zh) * 2008-07-19 2012-09-26 浙江家泰电器制造有限公司 液体加热器皿过热保护控制器组件
RU2454221C2 (ru) * 2010-07-06 2012-06-27 Общество с ограниченной ответственностью "Завод Медсинтез" Способ получения лиофилизированного противовирусного средства
EP2648755A1 (en) 2010-12-06 2013-10-16 Astron Research Limited A stable ready-to-use cetrorelix injection
GB201022147D0 (en) * 2010-12-31 2011-02-16 Immune Targeting Systems Its Ltd Formulation
CN102423484B (zh) * 2011-11-23 2014-01-15 深圳翰宇药业股份有限公司 一种稳定的西曲瑞克药物组合物及其制备方法
EP3015553A1 (de) 2014-10-30 2016-05-04 Biotecon Diagnostics GmbH Stabilisierte Reaktionsmischung
RU2667128C2 (ru) 2016-12-29 2018-09-14 Герман Петрович Беккер Композиция для приготовления противоопухолевого средства и способ приготовления противоопухолевого средства на ее основе
EP3982926A1 (en) 2019-06-17 2022-04-20 Intas Pharmaceuticals Ltd. A stable formulation of cetrorelix
CN112717119B (zh) * 2021-01-27 2024-04-30 南京羚诺生物医药技术研究院有限公司 一种西曲瑞克药物组合物及其制备方法
WO2022269572A1 (en) 2021-06-25 2022-12-29 Extrovis Ag Pharmaceutical compositions
CN114159544A (zh) * 2022-01-24 2022-03-11 福州华为医药技术开发有限公司 注射用醋酸西曲瑞克及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3816386A (en) * 1972-06-20 1974-06-11 Abbott Lab Purification process for gn-rh
DD141996A1 (de) * 1979-02-21 1980-06-04 Ingrid Wolf Verfahren zur herstellung von lyophilisierten lhrh-praeparationen
CS230614B1 (en) * 1982-08-06 1984-08-13 Martin Cs Flegel Analogues of realising factor for luteining and folliculstimulated hormon
US4565804A (en) * 1984-09-07 1986-01-21 The Salk Institute For Biological Studies GnRH Antagonists VI
EP0268066A3 (en) * 1986-10-17 1990-07-11 Syntex (U.S.A.) Inc. Fertility control and uterine therapy in dogs with luteinizing hormone releasing hormone antagonists
DE3735614A1 (de) * 1986-10-31 1988-07-28 Asta Pharma Ag Ifosfamid-lyophilisat und verfahren zu dessen herstellung
US4801577A (en) * 1987-02-05 1989-01-31 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
US5180711A (en) * 1990-06-14 1993-01-19 Applied Research Systems Ars Holding N.V. Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals
CN1036343C (zh) * 1990-11-10 1997-11-05 天津市计划生育研究所 新促黄体生成素释放激素拮抗类似物的制备方法

Also Published As

Publication number Publication date
SI9400087A (en) 1994-12-31
CN1112019A (zh) 1995-11-22
HUT67117A (en) 1995-02-28
NO940564L (ko) 1994-08-22
AU671881C (en) 2004-01-15
KR100372187B1 (ko) 2003-02-14
PT611572E (pt) 2000-11-30
EP0947200A2 (de) 1999-10-06
HRP940117B1 (en) 2001-02-28
SG46632A1 (en) 1998-02-20
ATE193653T1 (de) 2000-06-15
KR100355686B1 (ko) 2002-12-11
SK19594A3 (en) 1994-09-07
CA2115943A1 (en) 1994-08-20
DE4305225A1 (de) 1994-08-25
DK0611572T3 (da) 2000-09-25
CZ285768B6 (cs) 1999-11-17
TW387812B (en) 2000-04-21
NZ250906A (en) 1997-07-27
DE59409389D1 (de) 2000-07-13
IL108704A (en) 2005-05-17
GR3034237T3 (en) 2000-12-29
EP0947200B1 (de) 2015-03-11
NZ314707A (en) 1999-02-25
AU671881B2 (en) 1996-09-12
CZ31294A3 (en) 1994-09-14
FI940779A (fi) 1994-08-20
EP0611572A2 (de) 1994-08-24
IL108704A0 (en) 1994-05-30
ES2148247T3 (es) 2000-10-16
HU9400481D0 (en) 1994-12-28
SK283022B6 (sk) 2003-02-04
NO316601B1 (no) 2004-03-08
CA2115943C (en) 2003-08-05
EP0611572A3 (de) 1995-01-11
JP4033919B2 (ja) 2008-01-16
ZA941136B (en) 1994-08-29
CN1109557C (zh) 2003-05-28
UA43829C2 (uk) 2002-01-15
SI9400087B (sl) 2002-02-28
HU218281B (en) 2000-07-28
JPH06271476A (ja) 1994-09-27
EP0947200A3 (de) 2004-03-24
HRP940117A2 (en) 1996-08-31
MX9401312A (es) 1994-08-31
RU2145234C1 (ru) 2000-02-10
EP0611572B1 (de) 2000-06-07
FI940779A0 (fi) 1994-02-18
CZ284314B6 (cs) 1998-10-14
FI110059B (fi) 2002-11-29
NO940564D0 (no) 1994-02-18
AU5523594A (en) 1994-08-25
PL177177B1 (pl) 1999-10-29
BR9400617A (pt) 1994-09-27

Similar Documents

Publication Publication Date Title
SK283021B6 (sk) Spôsob výroby sterilného lyofilizátu cetrorelixu
US7605121B2 (en) Oligopeptide lyophilisate, their preparation and use
JP3065662B2 (ja) 副甲状腺ホルモン製剤
CH683749A5 (de) Pharmazeutische Nasalzusammensetzung.
DE4242863A1 (de) Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US20110201554A1 (en) Hfsh aqueous formulation
DE69819322T2 (de) Pharmazeutische zubereitung enthaltend peptide mit geringer löslichkeit in physiologischem medium
KR20030016426A (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법
US20180161401A1 (en) Novel Formulations of PTHrP Analogue
EP0417930A1 (en) Low-irritative nasal preparation
EP0331934A1 (en) New pharmaceutical compositions containing thymosin alpha 1

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20140218